Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant SOSLIV in hepatocellular carcinoma with preserved liver function
PACTR202411770822177Phase 2Not yet recruiting
- Sponsor
- Imo State University
- Start
- Jan 2025
- Countries
- 1
01
Overview
Phase 2, randomised trial in hepatocellular carcinoma (HCC) (3 arms), sponsored by Imo State University. Primary endpoints: Relapse-free survival and Time to symptomatic progression. Planned start Jan 2025; status: not yet recruiting.
02
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on PACTR202411770822177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202411770822177.